APOP

New Survey Reveals the Weighty Impact of Excess Weight for Dogs - and their Owners

Retrieved on: 
Wednesday, October 11, 2023
Food, Weight gain, Health, Obesity, OM, Emotion, Weight loss, Sibling, Pet, Overweight, APOP, Labrador Retriever, Love, Exercise, Dog, DVM, Nutrition, DIY, Quality of life, Pet industry, Purina

ST. LOUIS, Oct. 11, 2023 /PRNewswire/ -- A new survey1 from Purina Pro Plan Veterinary Diets, released today – National Pet Obesity Awareness Day – found that excess physical weight in dogs carries an emotional weight for their owners, and that many owners view their dogs as thinner than they really are. Results showed that approximately 1 in 5 dog-owning households consider one or more of their dogs to be overweight. However, according to the Association for Pet Obesity Prevention (APOP)2, the number of overweight dogs in the United States has reached a record high, with 59% of evaluated dogs in the U.S. either overweight (37%) or having obesity (22%).

Key Points: 
  • "Dogs do not always gain excess weight due to a lack of care from their owners", noted APOP President Ernie Ward, DVM.
  • "If anything, an overweight dog may be a sign that the owner cares too much about their dog's happiness.
  • The new survey revealed that excess weight gain in pets can be related to the emotions owners experience around feeding and treating:
    75% of surveyed owners agreed they feel guilty when their dogs appear hungry.
  • "While owners recognize that excess weight is keeping their dogs from participating in activities they once enjoyed, they also worry their dogs will be unhappy if feeding changes are made."

Keysight Enables First O-RAN Open Distributed Unit Fronthaul Certificate for ArrayComm through APOP

Retrieved on: 
Tuesday, March 28, 2023
Technology, Telecommunications, Software, Networks, Internet, Hardware, Electronic Design Automation, Data Management, Consumer Electronics, CAE, Network, Otic vesicle, Air Force Command and Control Integration Center, ArrayComm, Certification, Certificate of Conformity (Russia), UE, APOP, KORA, Ecosystem, NYSE, Medical device

Keysight Technologies, Inc. (NYSE: KEYS) has enabled ArrayComm to obtain the first O-RAN ALLIANCE Fronthaul Certificate of Conformance for its open distributed unit (O-DU) with the Keysight Open RAN Architect (KORA) solutions.

Key Points: 
  • Keysight Technologies, Inc. (NYSE: KEYS) has enabled ArrayComm to obtain the first O-RAN ALLIANCE Fronthaul Certificate of Conformance for its open distributed unit (O-DU) with the Keysight Open RAN Architect (KORA) solutions.
  • Awarded through the O-RAN ALLIANCE’s Certification and Badging program, ArrayComm’s Certification of Conformance verifies its O-DU is compliant with O-RAN fronthaul interface design specifications.
  • Today APOP reached another milestone of issuing the first O-DU Fronthaul Certificate of Conformance.
  • Peng Cao, Vice President and General Manager for Keysight's Wireless Test Group, said: “We congratulate ArrayComm for earning the first O-RAN O-DU Fronthaul Certificate of Conformance.

Keysight Enables MICAS to Obtain One of the First O-RAN Certifications for Open RAN Radio Unit

Retrieved on: 
Thursday, July 21, 2022
Technology, Telecommunications, Software, Networks, Internet, Hardware, Electronic Design Automation, Data Management, Consumer Electronics, Cloud, RIC, FR1, Network, ASTRI, UXA, NYSE, CEO, Research, Otic polyp, Control, KORA, Partnership, Solution, Compliance, House, Artificial intelligence, Air Force Command and Control Integration Center, Technology, Synchronization, Certification, CAE, Automation, Machine learning, Mobility as a service, ICT, Ecosystem, RAN, RF, FR2, Open, Keysight, Rail transport, Video game console, Medical device, Risk management, Digital badge, APOP

MICAS is a world class Independent Design House, providing signal chain reference solutions that include cutting-edge O-RU (FR1 and FR2) reference designs.

Key Points: 
  • MICAS is a world class Independent Design House, providing signal chain reference solutions that include cutting-edge O-RU (FR1 and FR2) reference designs.
  • We offer signal chain solutions with flexible options to the vertical industries leveraging our modular software and hardware.
  • We look forward to maintaining a close partnership with Keysight as we jointly deliver solutions for the verticals industries connectivity fabric.
  • Earlier this year, the O-RAN ALLIANCE launched its Certification and Badging program in cooperation with Open Testing and Integration Centers (OTIC).

Global Veterinary Orthopedics Market (2022 to 2027) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 8, 2022
Health, Other Health, Conditional sentence, Disorder, Injury, Arthropathy, American Veterinary Medical Association, Animal, Hip, Veterinarian, PETS, Government, Hospital, Risk, COVID-19, Dog, Adoption, Incidence, Cat, Obesity, Osteoarthritis, Association, APOP, CAGR, Cancer, Pet, Dentistry, Growth

The "Veterinary Orthopedics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Veterinary Orthopedics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Veterinary Orthopedics market is expected to register a CAGR of 7.5% during the forecast period.
  • This is attributing to the rising number of pet owners & veterinary practitioners, a growing number of government initiatives, increasing incidence of obesity.
  • Furthermore, with the growing adoption of pets, technological advancements in veterinary orthopedic devices and increasing government initiatives associated with animals will also fuel the veterinary orthopedics market.

The Worldwide Veterinary Orthopedics Industry is Expected to Reach $930 Million by 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 18, 2022
Veterinary, Health, Overweight, Dog, Arthritis, Zoonosis, APOP, Hip, Obesity, Joint, American Pet Products Association, PETS, Animal, Association, Cat, APPA, USD, Pressure, Prevalence, Osteoarthritis, Injury, Max, TTA, Dentistry, Pet, Medical device

Moreover, increasing technological advancements in veterinary devices is another driver expected to contribute to the market growth.

Key Points: 
  • Moreover, increasing technological advancements in veterinary devices is another driver expected to contribute to the market growth.
  • According to the American Pet Products Association (APPA), about 84.9 million American homes (67% of U.S. households) owned a pet in 2019.
  • The rise in the number of pet owners and, subsequently, expenditure on pets, is boosting the animal health industry, including veterinary orthopedics.
  • This can be attributed to the local presence of key market players undertaking extensive strategic initiatives
    Chapter 3 Veterinary Orthopedics Market Variables, Trends & Scope

Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals

Retrieved on: 
Friday, October 15, 2021
Transfer, Death, Cell, Technology, ADS, CVR, APOP, Nasdaq, Method, B cell, Eligibility, Mergers and acquisitions, Contingent value rights, SEC, Knowledge, Deposit, CVR Partners, Computershare, Clinical trial, Patient, GLOBE, Intellectual property, Fas ligand, Income tax, U.S. Securities and Exchange Commission, Company, Forward-looking statement, Review, Sale, Regenerative medicine, American, NASDAQ, Research, Partnership, Security (finance), Fine chemical

Following the completion of the Merger, the Company will be renamed Quoin Pharmaceuticals, Ltd., and will trade on the Nasdaq Capital Market under the symbol QNRX.

Key Points: 
  • Following the completion of the Merger, the Company will be renamed Quoin Pharmaceuticals, Ltd., and will trade on the Nasdaq Capital Market under the symbol QNRX.
  • Each holder should consult with a tax advisor regarding the tax implications for such holder.
  • Cellect Biotechnology (APOP) has developed a breakthrough technology for the selection of stem cells from any given tissue that aims to improve a variety of cell-based therapies.
  • Any forward-looking statement in this press release speaks only as of the date of this press release.

Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals

Retrieved on: 
Monday, September 27, 2021
Transfer, Clinical trial, Regenerative medicine, Plan, Special, Review, Compliance, Risk, Annual report, Sale, NASDAQ, U.S. Securities and Exchange Commission, Listing Rules, Patient, APOP, Income, Corporate action, BMT, Lymphatic system, IP, Method, CA, Company, LLC, Knowledge, Listing, Agreement, Technology, Washington University in St. Louis, Research, Fas ligand, Cell, Forward-looking statement, Intellectual property, B cell, SEC, GLOBE, Pharmaceutical industry

Approximately 99% of the votes cast on the strategic merger agreement at the Special General Meeting voted in favor of approving the proposal.

Key Points: 
  • Approximately 99% of the votes cast on the strategic merger agreement at the Special General Meeting voted in favor of approving the proposal.
  • Subject to the satisfaction or waiver of all other closing conditions, the strategic merger is expected to close in October, 2021.
  • The Agreement and Plan of Merger and Reorganization has been amended by the parties therein to extend the Outside Date thereunder from September 30, 2021 to November 1, 2021.
  • Following the completion of the strategic merger, Cellect will be renamed Quoin Pharmaceuticals, Ltd., and will trade on the Nasdaq Capital Market under the symbol QNRX.

Cellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantation of First Patient in U.S.

Retrieved on: 
Thursday, September 2, 2021
Patient, Achievement, BMT, B cell, GVHD, Cell, Review, U.S. Securities and Exchange Commission, Leukemia, Forward-looking statement, Intellectual property, Method, Washington University in St. Louis, SEC, APOP, Lymphatic system, Company, Knowledge, Haematopoietic system, Research, Clinical trial, Technology, Professional, GLOBE, Fas ligand, NASDAQ, Regenerative medicine, Pharmaceutical industry, Fine chemical

The trial will enroll 18 patients with hematological malignancies who are undergoing a haploidentical Bone Marrow Transplantation (BMT).

Key Points: 
  • The trial will enroll 18 patients with hematological malignancies who are undergoing a haploidentical Bone Marrow Transplantation (BMT).
  • EnCellX, led by Founder and CEO Adi Mohanty, is raising funds from leading healthcare institutional investors to expedite and expand clinical development.
  • We look forward to working closely with EnCellX as its U.S. based team will work closely with Washington University to continue patient enrollment.
  • The Companys current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Cellect Biotechnology Reports Second Quarter 2021 Financial and Operating Results

Retrieved on: 
Tuesday, August 24, 2021
Company, Record, U.S. Securities and Exchange Commission, GLOBE, Regenerative medicine, SEC, Method, Knowledge, Research, Fas ligand, B cell, CPA, F4, Risk, R, APOP, Intellectual property, Cell, Forward-looking statement, CFO, American, G&A, Review, Clinical trial, NASDAQ, Mass meeting, Patient, NIS, FDA, Annual report, American depositary receipt, Technology, Security (finance), Fine chemical, Pharmaceutical industry, Coal, Lithium

Tel Aviv, Israel, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, today reported financial and operating results for the second quarter ended June 30, 2021, and provided an update on the proposed strategic merger with privately-held Quoin Pharmaceuticals and recent clinical news

Key Points: 
  • Separately, Yaron Ben-Oz, CPA, will be joining the Company as Chief Financial Officer, effective September 1, 2021.
  • General and administrative (G&A) expenses for the second quarter were $0.86 million compared to $0.65 million in the 2020 second quarter.
  • Finance expenses for the second quarter of 2021 were $0.43 million compared to finance expenses of $1.63 million in the second quarter of 2020.
  • Total comprehensive loss for the second quarter was $1.7 million, or $0.004 per share compared total comprehensive loss of $2.7 million, or $0.007 per share, in the second quarter of 2020.

The Securities and Exchange Commission Declared Cellect Biotechnology’s Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharmaceuticals

Retrieved on: 
Friday, August 13, 2021
Method, Forward-looking statement, NASDAQ, U.S. Securities and Exchange Commission, Intellectual property, Form, APOP, Clinical trial, Company, Risk, Mass meeting, GLOBE, F-4, SEC, Cell, Research, FDA, Annual report, Security (finance), Patient, Technology, Knowledge, Regenerative medicine, B cell, Review, Fas ligand, Pharmaceutical industry

Tel Aviv, Israel, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, announced that its registration statement filed on Form F-4 with Securities and Exchange Commission (“SEC”) on August 10, 2021 was declared effective by the SEC on August 12, 2021 (the “Form F-4”). The Form F-4 was filed in connection with the previously announced strategic merger with Quoin Pharmaceuticals, Inc., a privately held U.S. based company focused on rare and orphan diseases.

Key Points: 
  • The Form F-4 was filed in connection with the previously announcedstrategic merger with Quoin Pharmaceuticals, Inc., a privately held U.S. based company focused on rare and orphan diseases.
  • Additional information regarding the proposed strategic merger can be found in the Form F-4.
  • Cellect Biotechnology (APOP) has developed a breakthrough technology for the selection of stem cells from any given tissue that aims to improve a variety of cell-based therapies.
  • The Company's lead product is currently in FDA approved clinical trial is aimed at bone marrow transplantations in cancer treatment.